Idera News
Most Popular Idera Story
Idera's cancer drug disappoints in Phase II
Cambridge, MA-based Idera Pharmaceuticals is reporting disappointing preliminary results from a Phase II trial of IMO-2055. The primary endpoint--tumor response based on RECIST (response evaluation Read more...
Latest Headlines
- October 1, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
